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The introduction of open source in the life sciences is increasingly being suggested
as an alternative to patenting. This is an alternative, however, that takes its shape at
the intersection of the life sciences and informatics. Numerous examples can be
identified wherein open source in the life sciences refers to access, sharing and
collaboration as informatic practices. This includes open source as an experimental
model and as a more sophisticated approach of genetic engineering. The first
section discusses the greater flexibly in regard of patenting and the relationship to
the introduction of open source in the life sciences. The main argument is that the
ownership of knowledge in the life sciences should be reconsidered in the context
of the centrality of DNA in informatic formats. This is illustrated by discussing a range
of examples of open source models. The second part focuses on open source in
synthetic biology as exemplary for the re-materialization of information into food,
energy, medicine and so forth. The paper ends by raising the question whether
another kind of alternative might be possible: one that looks at open source as a
model for an alternative to the commodification of life that is understood as an
attempt to comprehensively remove the restrictions from the usage of DNA in any
of its formats.
Keywords: Open source; Life sciences; Informatics; Synthetic biology; Patents;
Genetic engineeringIntroduction
The title of this article – open genetic code – refers to the introduction of open source
in the life sciences. The analogy is straightforward: open source is about the free availability
of information, which includes information on genes, proteins, cells and so forth. What
such a definition leaves unexamined, however, is its interpretation of 'free' and 'open' at the
intersection of the life sciences and informatics. What does such an alternative to patenting
mean when moving from examples that are directly equivalent to informatics and the
response by the open source movement to the commodification of source code to the life
sciences where markets and technologies are transforming the usage of DNA?
The suggestion that open source in the life sciences is an alternative to patenting in
the life sciences typically refers to an attempt to solve the tragedy of the anticommons.
What is tragic is than a situation wherein there are too many parties hold exclusive
rights over access that are obstructing the usage of technologies, resources and
the production of knowledge (Heller 1998, Heller and Eisenberg 1998). To solve theDeibel; licensee Springer. This is an open access article distributed under the terms of the Creative Commons Attribution
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium,
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“openness” in the life sciences, which takes the shape of trading and cross-licensing of
patents as well as the arrangement of access by way of collaborative research projects,
joint ventures, private consortia and public–private partnerships (see Allarakhia 2007).
Most commentators have interpreted the introduction of open source in the life sciences
along these lines: as a response to the proliferation of patents analogous to the example
set by the open source movement in informatics (see Burk 2002; Reichman and Uhlir
2003; Boettiger and Burk 2004; Opderbeck 2004; Hope 2008, 2009; Overwalle 2009;
Allarakhia and Wensley 2005, 2007; Rai & Boyle 2007).
However, there are various types of resources and knowledge in the life sciences that have
become market-based over the last decades. Crucially, this includes the values of openness
and collaboration in the life sciences, which are not necessarily the attributes of academic
projects wherein commercial imperatives have no place (Kleinman and Vallas 2006).
Openness in the life sciences as an increasingly regulated and commercialized activity
represents a considerable strategic and economic value when situating the decision not to
pursue patent strategies within the context of a 'contestation over the very definition of
what constitutes market logic' and in terms of its 'implications for the overall terrain of
cooperation, conflict and value generation' in the life sciences (Sunder Rajan 2006: 58,
Sunder Rajan 2003). This does not imply that that the introduction of open source in the
life sciences does not have any potential as a 'defense of the public domain' or as a new
kind of commons that is noncommercial (see Lessing 2001: 262, Benkler 2002, 2006, see
Boyle 2003a, 2003b, 2008). However, there should be little surprise about how many of
the alternatives to patenting resemble an organizational setting wherein innovation
involves start-up companies, venture capital, stock markets and other kinds of financial
speculation (see Cooper 2008).
The first section discusses the greater flexibly in regard of patenting and the relationship
to the introduction of open source in the life sciences. The main argument is that the
ownership of knowledge should be reconsidered in relation to the centrality of DNA in
informatic formats. A range of examples of examples of open source models illustrate the
convergence with informatics and show an alternative that takes shape as informatic
practices, artifacts and related sets of knowledge in the life sciences. The objective
of this part of the analysis is to turn the discussion away from a juridical understanding of
openness that remains closely tied to patenting and towards an analytical position in
respect of the redefinition of openness in the life sciences. Accordingly the main argument
of section one is that the introduction of open source in the life sciences is a reflection of
the expression of DNA in a digital or electronic form to be ‘acted upon and interacted
with in ways that would not otherwise be possible’ (Parry 2004, 65; see also Pottage 2006).
Subsequently the second section focuses on synthetic biology, which has in a short period
become exemplary for open source as an experimental model and as a more sophisticated
approach of genetic engineering.
This part of the article describes in some detail the exchange of synthetic DNA,
which sharpens the argument by moving from a focus on “how” knowledge and
resources are being shared to a setting that can be reconsider in terms of “who” gets to
be a contributer in a field that aims to re-materialize information that is freely available
as food, energy, medicine and so forth. More specifically, the introduction of open
source in synthetic biology brings together the flexibility in regard of patenting with an
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discussion section on the implications of these limitations on the analogy with open
source that is being drawn and signals at the possibility of exploring the realization
of a different kind of alternative. Rather than aiming to involve more contributers
in experimentation, the analogy could be modeled on the response to the commodification
of source code by attempting a much more comprehensive removal of restrictions on
DNA, whether as source code, as genetic sequence or as biodiversity, seeds and other kinds
of living materials (see Deibel 2006, 2009).Open source and the convergence of the life sciences and informatics
The language of biological life has become increasingly informationalized since the
mid-twentieth century in its emphasis on complexity, adaption, emergence and so on.
The dissemination of this informatic paradigm continues today with the integration of
molecular genetics and cell biology with fields such as mathematics, statistics and
informatics (Doyle 1997; Kay 2000, Fox Keller 2002; O’Malley and Dupré 2007).
The emphasis on information is therefore at once a way of thinking that developed
throughout the twentieth century and a way of acting revolving around informatic
practices and the usage of informatic artifacts. The latter is particularly significant
when focusing on the sharing of resources in terms of the 'technological and economic
management of information – that is, as a political economy’ (Thacker 2005: 94,
Thacker 2003, Haraway 1997, Parry 2004).
Patenting has as its aim to reward inventions by granting exclusive rights that
enable temporary monopolies that make it possible to recover the required investments
(see Rutz 2009). This includes the life sciences where patenting was introduced in the
early eighties by extending the technical criteria for the patenting of chemical compounds.
The life sciences were incorporated into the regime for chemistry where patenting had
developed in response to advances and industries related to organic chemistry in the late
nineteenth century, including the appearance of research laboratories in corporations
(Dutfield 2003).
More specifically the patent regimes for the life sciences can be traced to the ruling
of the US supreme court in the early eighties that established that DNA could be a
'technical' subject'. The implication of this decision was that legally speaking certain
types of DNA were designated as a 'composition of matter' and a 'product of ingenuity'
rather than a 'manifestation of nature' (Parry 2004: 85). Alongside the question whether
patents encourage innovation, controversy has remained over the desirability of a
patent system in areas like the genetic modification of food, medicine and elsewhere
(see van Dooren 2007, 2009). Despite of the various and continuous controversy
the initial ruling has been followed by numerous others in the US and around the
world that expanded the scope of patenting. Amongst these is the patenting of the
isolation of DNA in a purified form; as sequenced stretches of DNA (Carolan 2010). This
can be considered useful; the main condition is that the DNA was not purified before and
it makes no difference that the living form from where the DNA was taken might have
already existed for quite a while.
What is significant for this paper, however, is how purified DNA is oftentimes not
considered as a 'composition of matter' by analogy to patenting in chemistry but as
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ensure the reproducibility of the invention by making information public. Accordingly
the invention has to be described in the application and the information is released to
the public when the grant expires. However, it is only under certain conditions and
with considerable difficulty can informatic practices be identified with DNA that has
stable chemical properties (Calvert and Joly 2011, Caulfield 2011). On the one
hand, the legal process continues to separate DNA as a “composition of matter”
from DNA as information which is not patentable. On the other hand, the life sci-
ences and informatics are no longer as different as scientific domains and indus-
tries as they were in the early eighties when patenting was introduced.
Both these interpretations can be applied to a recent case: the invalidation of the
patents of Myriad Genetics for two genes with mutations that cause cancer
(BRCA1 and BRCA2) by the US supreme court. The company patented these two
genes as diagnostic tools for the testing of breast cancer and therefore Myriad can
ask higher prices for its tests and restrict access to medical information acquired
through these tests. The case got a lot of publicity because of the suggestion that
there would be stricter criteria for patenting in the US; what is significant, however, is not
only whether or not the legal criteria of patenting are changing but that diagnostic tests,
like Myrad's, are quintessentially about the invention and usage of informatic artifacts and
related practices. What the case shows is that the patentability of DNA that has
been isolated and purified presumes an analogy with chemistry while the tests revolve
the identification of gene sequences and expressions of a patient by comparison
with information in a database (Caulfield 2011, Rodgers 2010, see Carolan 2010).
More specifically the difference between DNA as chemistry and as information was
recognized by the judges. The original ruling by the judge of the District Court had
invalidated the patents with the observation that the DNA involved was known through
its 'information content, its conveyance of the genetic code'. Similarly the final ruling
by the supreme court explains that Myriad's claims are not expressed in terms of chemical
composition and did not create or alter the genetic information encoded in the genes
or the genetic structure of the DNAa Accordingly Myriad's diagnostic tests are an
illustration of the conceptual difficulty and work involved in turning DNA into a
biological object that can be patented (Vermeulen et al. 2012). This observation
applies to less well-known cases, particularly the attempts to patent models of networks of
genes and proteins, which is much more difficult than when patenting a single expression
of a gene (Allarakhia and Wensley 2005: 1486). These network patents are sometimes
granted in the US and the EU but not many; it is exceedingly difficult to isolate
the patentable attributes of networks of genes that are modeled as interactive and
related to a wider biological context in its complexity (see Calvert 2007, 2008).
Furthermore the practice of presenting an invention based on DNA that is sufficiently
chemical to be patenting can be reconsidered as a relationship between the ownership of
knowledge and an increasingly complex and fragmented notion of life at a molecular scale
that is known by way of an ‘information paradigm’ corresponding to a configuration
of ‘institutions, procedures, instruments, practices and forms of capitalization’
(Rose 2001, 13–15). Its implication is that the legal focus on DNA as a compositions of
matter is situated in the context of the convergence of the life sciences and informatics
alongside the introduction of open source models. Both the informatic attributes that are
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high quality access to interactive databases and software reflect a transformation of the
usage of DNA in the life sciences.
The remainder of section one has as its objective to show that the introduction of
open source models in the life sciences reflects the usage of informatic artifacts – like
software, databases, hardware and so on – and related practices like downloading, copying
and searching of information around the world via the Internet. What this demonstrates
is that there is nothing “idealistic” about discussing open source in the life sciences: there
are many examples when including those that are directly equivalent to informatics
(open source software, databases and the computing requirements of data-driven research).
Crucially, however, the convergence with informatics implies that open source models are
integral to the interpretation of processes of gene expression and regulation and sequences
that can be cut, spliced and transcribed in different ways. This does not imply that genetic
code and source code are, should or will be the same; examining the re-definition
of openness shows that the priority given to the digital in experimental settings
corresponds to a reconfiguration of ownership, institutions and practices.Open source and bio-informatics
When discussing patenting in the life sciences, whether as a critique or its relative
merits as a means to encourage innovation, it is important to realize that there are
other means whereby to establish ownership over biological objects. For example there
are many different kinds of intellectual properties for source code that were introduced
for source code around the same time as patenting for genetically modified organisms.
Another option, however, is to release the information by using the open licenses that
have become increasingly widespread.
When the scope for patenting DNA no longer increases, other kinds of intellectual
properties could become more relevant. For instance there are software patents on a
processes that make computers run faster, on the interaction with a program or by
some other way whereby efficiency has been increasedb. Similarly source code and
information in databases are considered legally equivalent with written text, meaning
that they can be copyrighted. However the limitations on the scope of DNA patenting,
as in the Myriad case, do not necessarily lead to other kinds of intellectual property or
related forms of ownership over knowledge. Another option has become a possibility in
line with the response to the extension of intellectual properties to source code in the
early eighties.
Specifically, the Free Software Foundation (FSF) has aimed to counter the restrictions
on the usage of source code that became possible by extending intellectual property to
software development.
Its founder Richard Stalllman started the FSF in the early eighties and most commentators
point to his release of the source code that he had programmed himself, which he made
available on the condition that those that used it would do the same. When they used his
programming, the end-result should be freely available. Notably Stallman could decide to
re-interpret his copyright, which does not need to be registered; it is automatic, for novels,
newspaper articles, music and at that moment also for the ones and zeros of source code.
This is crucial; Stallman did not renounce the copyright that had been introduced but used
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preventing that programmers of source code and users of software would loose the freedom
to control part of their own lives.
By creating the General Public License, the GPL, it became possible for Stallman to
release the software that he programmed with the aim of enabling others to use, study,
copy, modify and redistribute its source code. The aim is to make software 'free' on the
basis of four freedoms:
– the freedom to run the program, for any purpose
– the freedom to study how the program works and adapt it to your need;
– the freedom to redistribute copies so you can help your neighbor;
– the freedom to improve the program, and release your improvement to the public,
so that the whole
– community benefitsc.
The GPL was the first of the many different kinds of open licenses that are by now
used throughout informatics and in many other domains. The most widespread
examples are the well-known Creative Commons licenses that are being used for text,
images, audio, video productions, architectural design as well as for software and
databases wherein information is stored on maps of genomes, proteomes and metabolomes
and so forth. Such open licensing, however, is used in a more pragmatic sense that is closer
to the connotations of the term 'open source'. This is a term that was introduced much
later, in the nineties, and it emphasizes the efficiency of sharing and collaboration in
informatics. It explicitly intended to replace the idea that free software would be
available without any costs, which was considered inappropriate in the corporate
world (see Berry 2004, 2008). Open source does not focus as much on the freedom of the
users of software; it placed more emphasis on the technical issues of software
development and emphasizes that it is the programmer of source code that owns
it. Code is ‘property owned by an individual who has the right to control and develop it’
(Berry 2004: 81, Raymond 1999).
Similarly the success of the open source projects is explained by programmers that
choose to contribute the source code they wrote to projects that use an open licensing.
Under certain conditions such projects are more efficient than other projects; open
source and 'closed source’ are then not about freedom but simply different development
models that are more or less efficient under different circumstances. In this respect the
thousands of projects illustrate efficiency, a technical orientation and economic sense
rather than an alternative that is primarily about freedom. This point of view was already
part of the discussion over whether the human genome project was already an 'excellent
example' of open source in the life sciences (Opderbeck 2004: 21, Allarakhia 2007).
The various laboratories around the world used research standards that had to be
flexible to integrate their methodologies and some even developed open source
software. However, it was also decided by those running the human genome project
that open source would be too controversial (Cukier 2003). The databases with
sequence information on the human genome were made publicly accessible for
everyone without the condition that enforced the sharing of this information in
other formats (Sulston and Ferry 2002: 222).
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of usage of the information in a database. On the one hand, this is not limited to the
human genome but counts for most of the incredible amounts of information in
various sub-disciplines of the life sciences. For example there are 100 giga bytes of
sequenced DNA compiled in the GOLD database alone and similar databases exist for
the 100.000 or so human proteins that make up the proteome as well as for spliciomics,
metabolomics and so forthd. This is information that is available for further research
but does not use open licensing. There is, on the other hand, already open licensing for
databases with the aim of guaranteeing the future availability of information. For
example there are many different kinds of databases that use the 'science commons'
license, like the major protein database called the neurocommons and the hapmape.
The main aim of these this type of open licensing is to avoid that other intellectual
property claims impede the access to the data by other users and to facilitate this usage
(see Gitter 2007).
The availability of the information is integral to the interaction of researchers with a
wide range of datasets being used in the different sub-disciplines of the life sciences.
This includes many examples of open source projects with users around the world like
the the bio-versions of programming languages like are bio- java, bio-perl, bio-spice,
bio-harvester and bio-lisp. Each of these has its own voluntary or public science
support communities like the Open Bioinformatics Foundation. Elsewhere there are
numerous projects in bio-informatics that aim for a wide range of open source software
tools for the analysis of data. For example there is Bio-SPICE a software tool set that is
specially designed for research into the modeling and simulation of ‘spatio-temporal
processes in living cells’. Its website describes Bio-SPICE by writing: “Bio-SPICE, an
open source framework and software tool-set for Systems Biology”f.
Finally, these programs illustrate the significance of the ability to rewrite software
programs for asking novel biological questions, which is necessary in many different
kinds of experiments. The point is therefore not only that there are some software
programs in the life sciences that are open source whereas most are not; open
source is integral to forms of experimentation that depends on constant coordination
of a 'multiplicity of techniques coordinated on an elevated surface (the screen)'
(see Mackenzie 2010: 189). Crucially, the introduction of open source in the life
sciences is therefore not a feature of patenting or the proliferation of exclusivity. This is
an alternative that takes its shape at the intersection with informatics and as a necessary
part of questioning the biological, which is too limited in the case of preprogrammed
homology searches of databases or software programs that already make information
available in the public domain. This difference is significant: it implies a changing
relationship between 'openness' and exclusivity that runs throughout the the life
sciences and that requires increasingly wide variety of researchers with highly
specialized knowledge and different levels of commitment to work together.Common-based strategies
Freely available source code and the ability to rewrite the programming of a particular
kind of software or database are significant as examples of the re-definition of openness
in the life sciences. The various examples that were mentioned are integral to the
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complex research settings wherein massive amounts of data need to be computed
and interpreted. Again there are various kinds of open source models involved,
which show how the rise of bio-informatics implies that the sharing of information
has become a norm and how open source is one of the more efficient way of processing
information about life as essentially complex and interactive.
Consider a project called 'folding@home', which is one of Yochai Benkler's counter
examples to the suggestion that drug development is too complex, expensive and
time consuming for non-commercial projects based on 'common-based strategies'
(see Benkler 2006: 83, 351).What is special about this project is that it models the
folding of three-dimensional proteins that might cause diseases on the basis of
“voluntary” contributions. Its calculations are made by involving millions of volunteers in
a internet-based distributed computation projects (ibid). The contributors do nothing
more than to install a small client program that runs on unused capacities of
their PCs, which enables packages of data to be sent periodically. However the
project is not open source; folding@home does not allow for modification of the
programming and redistribution of the data by its collaborators, which raises the
question whether there is a difference with 'common-based strategies' that do have
these characteristics.
Folding@home became faster than any single supercomputer in 2007, surpassing the
petabytes and tetraflops of Blue Gene, a supercomputer build by IBM that is specially
developed for experiments in the life sciences (Noble 2006: 65–67). These types of
computation are needed to create situations and models of life, which requires the
processing of enormous amounts of information. Notably Blue Gene runs on Linux,
which is ‘the key working example' of open source as 'a collective project that has been
shared and worked on freely’ (Berry 2004: 80). Therefore supercomputing and hardware
are an integral part of the introduction of open source in the life sciences and signal that
its scope includes the various types of computational modeling within experimental
set-ups. For example the Blue Brain Project, is one of several wherein Blue Gene is
used: its objective is to 'to reverse engineer the human brain and recreate it at the
cellular level inside a computer simulation' with the aim to develop brain disease
treatmentsg. The experimental side to the convergence with informatics foregrounds the
specificity of the interface between the life sciences and informatics. The question that is
most important when redefining openness as something primarily informatic is about the
scope of collaborations. Benkler's interprets the various kinds of informatics projects
in the life sciences by pointing out the differences in ‘the number of people who
can, in principle, participate in a project’, which he explains as: ‘inversely related to
the size of the smallest scale contribution necessary to produce a usable module’
(Benkler 2006: 101). Accordingly the modularity of a project might be about distributed
computers involving millions or smaller scale efforts with fewer contributers that are
more specialized. The former applies to examples like folding@home whereas the latter
applies to the collaboration in open source software project, which is widely distributed
and involves loosely connected individuals who cooperate with each other for a diverse
range of motivations wherein contributors can choose what and when to contribute
independently of each other (ibid). The modularity of the different project is deter-
mined by the total amount of potential contributors, which decreases in magnitude
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skilled contributors on some specific component of a project (see Benkler 2002, 2006).
On the one hand the emphasis on the modularity of the projects suggests a
commons-based strategy for research networks in the life sciences that are in the
process of becoming more collaborative, gradual and global as digital environments
(Ewan 2004). Such networks revolve around the ability to contribute, which is the
objective of many open source project. A simple example might be the ability to track
changes in the source code is complimented by repositories for revisions of other kinds
of data (see Dietz et al. 2012). On the other hand the open source model can be
distinguished as a common-based strategy that revolves around increasingly informatic
ways of thinking about life an nature. Such an open source project aims to achieve the
objective of finding contributers by prioritizing the biological over the informatic.
A first example is a project called “Open Worm”. Its aim is similar to the other types
of software projects that were discussed; it seeks contributers to program a complicated
piece of open source software to simulate the behavior of a microscopic roundworm
with a relatively low amount of cells. What is significant, however, is the projects tag-line,
which equates its efforts with: “building the first digital life form. Open Source”h. Such
emphasis on the “building of life” is primarily discursive and might be contrasted to many
similar attempts to understand cell behavior that do not emphasize the life-like qualities
of their models (Figure 1).
The reason, however, that this is a significant example is an indicator at the overlap
between open source programming in the life sciences and synthetic biology. This field
has quickly become exemplary for its application of open source principles to genetic
engineering. So far the discussion has outline the varies types of examples of open
source in the life sciences, showing that the alternative to patenting takes a shape that
is directly equivalent to open source in informatics. Accordingly the patenting of DNA
is not the primary setting for examining the sharing of resources among life scientists;
there are various fields that are engaging directly with informatics, which includes open
source programming, databases and hardware as integral parts of experimental set-ups.
The implication is not that there will be no patents or the various controversies will
be settled; these are likely to intensify as more legal work will be needed to separate
DNA as a composition of matter from DNA as an informatic entity. The same applies
to how the digital can be prioritized strategically and selectively in relation to life as a
technological creation, whether as a medicinal test, a genetically altered crop, a biofuel
or otherwise. This is shown in section two: the aim of focusing on synthetic biology isFigure 1 Image taken from the website of the OpenWorm project on the 13th of May 2013,
see http://www.openworm.org/.
Deibel Life Sciences, Society and Policy Page 10 of 232014, 10:2
http://www.lsspjournal.com/content/10/1/2to examine the analogy with open source in the context of the re-materialization of the
freely available information. The widening scope for collaboration can be followed from
the convergence with informatics to an emerging open source philosophy that is
closely related to a business model, to the governance of risk and a notion of
openness that is limited to a design process that benefits from the involvement of the
users of synthetic DNA.Open source as an approach to genetic engineering
Discussion over the introduction of open source in the life sciences increasingly
revolves around the field of synthetic biology. Specifically the activities of the BioBricks
Foudation are being showcased as an illustration of sharing and collaboration as integral
to the aspiration of designing and engineering 'biological parts, devices and systems' for
'useful purposes’ (see Rathenau Institute 2006).
Many of these parts are being patented and are becoming difficult to use, which is
one of the principle reasons for the BioBrick™ Public Agreement. This is an open licensing
scheme in the spirit of the General Public License (GPL) introduced by the BioBricks
Foundation: 'to make free the sharing of any genetically encoded function that you might
already own or make anew' and to ensure 'that the engineering of biology is conducted in
an ethical manner to benefit all people and the planet'i.
Accordingly a design community is organized around biological parts that are freely
available. There is an on-line registry where biological parts, called BioBricks™, are
published as modules that have been standardized to perform a biological function
and that 'has been engineered to meet specified design or performance requirements’.
These parts can then be attached to others in different combinations as ‘functional inputs
and outputs’ that are being referred to as biological equivalents of sensors, logic gates and
actuators (Canton et al. 2008: 787).
Such an approach to genetic engineering has led commentators to recommend a
‘mix of patent and open source incentives [that] is most likely to deliver the cheap
and abundant part that synthetic biologists (and by implication, the world) needs’
(Henkel & Maurer 2007: 1). In this regard the activities of the BioBricks Foundation are
considered as exemplary for the ability to find alternatives to the tragedy of the anticom-
mons by arranging access and guaranteeing 'openness' alongside the proliferation of
patenting elsewhere (see also, Rai & Boyle 2007, Kumar & Rai 2007)j. Furthermore there
is widespread admiration for the ‘elegance and playfulness of the programming of the
hacker culture of software engineering’ (Brent 2004: 1213–1214). Such an analogy with
open source seeks an approach to genetic engineering that is comparable to informatics
in its ‘quest to understand the quantitative biology of function’ wherein it becomes a
matter of coding and programming ‘design tools’ (ibid, see also Knight 2005).
Crucially, however, it is mainly in a rhetorical sense that the biological parts of the
BioBricks foundation can be compared to well-behaved Lego-like entities that are safe and
secure according to protocol. Any BioBrick, despite of the emphasis on standardization
and modularity, continues to mutate and show variation in ways that could interfere with
its performance. A synthetic system could bind to pre-existing pathways of any of
its biological parts in unexpected ways. In effect, there is always some amount of
the biological complexity that will be left in place; even when there is no interference with
Deibel Life Sciences, Society and Policy Page 11 of 232014, 10:2
http://www.lsspjournal.com/content/10/1/2its functionality, there will be interactions of multiple genes, feedback loops and so forth
(Arkin & Fletcher 2006).
Complexity and lack of understanding do not imply that synthetic biology could not
become highly effective in its approach of genetic engineering. What is significant is
that the exaggeration spills over from an experimental approach to the legal domain;
the open source model is simultaneously a means to attain an exception to patenting
and create an interface with the governance of innovation. On the one hand, this is
highly desirable: who would object to an open source model that is presented as something
ethical with the aspiration to be beneficial to the people and the planet, as its website
mentions? On the other hand, there is a closely related business model in synthetic biology
that shows the relationship to the usage of informatic practices and artifacts, which was the
main argument of section one. Furthermore examining the analogy with open source
informatics in detail shows its limitations: while experiments of synthetic biology might
become much more collaborative and modular, there are clear limits when considering its
open source model as policy advice or a wider variety of restrictions on the usage of DNA
that might need to be removed in order to realize its ethical aspirations.The exchange of synthetic DNA as a business model
Open source in synthetic biology subscribes to the underlying value of the patent system,
which is the acceleration of the development and introduction of novel technologies
(see Hilgartner 2012:192). In addition the exchange of synthetic DNA resembles the
formation of informatic markets and informatic commodities.
Consider Blue Gene again: this time as a project that combines an implication of
Linux with the business model of IBM. Open source models have become so successful
in informatics that they are by now an integral part of the competitive strategy of many
of its major companies. Even though Linux represents the greatest achievement that
open source has been capable of, it is with ease that it has been 'slotted into corporate
software production at companies such as IBM, Compaq, Hewlett Packerd, Apple, and
Sun Microsystems' (Mackenzie 2005: 72). What this suggests is that the scope of
collaboration in the life sciences is at once an experimental setting, focused on the
complexity of the modeling of cells, and a feature of the formation of markets for
sophisticated hardware, software and other informatic artifacts that are being used
throughout the life sciences. This includes the business model of synthetic biology,
which is informatic in the sense that the freely available information in databases can
be re-materialized into experimental samples that are improved, optimized or altered in
respect of one or more of its properties.
Specifically the business model of synthetic biology revolves around the supply of genes
and genomes that are standardized on demand. Scientists could do this kind of synthesis
themselves but this would be time-consuming and the prices of DNA synthesis are
dropping fast. Examples of companies that specialize in putting together long and
complicated pieces of synthetic DNA include Blue Heron Technology, Coda Genomics,
GeneArt and DNA 2.0 (Bügel et al. 2007 Rathenau Institute 2006). The competition of
these companies revolves around the efficiency of accessing information and its effective
integration into experiments that represent genes and proteins in countless variants in
order to identify the most effective one as a digitalized network of reactions.
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by the J. Craig Venter Institute for 101 specially designed fragments of synthesized
DNA from some of these same companies. These pieces of synthetic DNA were that
were put into a yeast cell to be assembled into a 'living bacterial cell based entirely on
the synthetically made genome' by the repair mechanisms of yeast as a step towards
the ability to create cells that could behave as instructed by the synthetic genomek.
Most attention has gone to the question whether this experiment has resulted in the
first artificial life form; here the observation is merely that the business model of synthetic
biology involves very few patents and revolves around freely available information to be
re-materialized as experimental samples.
When attempting to be able to ‘plug in' energy, food, or health modules into living
materials there is no contradiction between the free availability of genetic techniques
considering the involvement of the main protagonists of the BioBricks foundation in
Codon Devices. Accordingly the centrality of DNA in informatic formats (discussed in
section one) can be followed to the founding of this company in 2004 with venture
capital that aimed to become a platform for synthetic biology. Notably this has failed:
Codon attempted to combine the delivery of synthesized DNA with the design for
applications but in 2009 it went out of business. There is little profit in the synthesis of
DNA, which is becoming cheaper and it was not successful in finding customers for the
design of applicationsl. The failure is significant because it shows that the production
process of synthetic biology is not yet effective and how the success of the BioBricks
foundation and related experimental set-ups might fill the gap between the exaggerated
informatic rhetoric about genetic engineering and the attempts to commercialize the
exchange of synthetic DNA.
Prioritizing an open source philosophy for synthetic biology gives a very different
impression than when foregrounding how synthetic biologists are attempting to create
synthetic modules to be plugged into living materials and to generally expand the scope
for turning synthetic DNA into profitable types of products. On the one hand, the
business model of synthetic biology can be seen as a production process that is only
complete when finding ways to capture profits from whatever synthetic compound is in
demand on world markets – plastics, chemicals, oil etc. Currently numerous types of
experiments are being done on synthetic equivalents for breaking down toxins, the improve-
ment antibodies as well as bioplastics, biofuels and medicines (See ETC Group 2007a, b).
On the other hand, many of the experiments are not directly profit oriented even though
they are similarly linked to the cheap and easily accessible samples delivered by the
various companies in synthetic biology.
The combination with open source as an approach to genetic engineering foregrounds
how effortless a ground-breaking new field might become an inclusive and ethical
alternative to patents on DNA and the monopolization of knowledge. An example
that is frequently mentioned in this regard is Jay Keasling’s wok on eradicating a
parasite that causes malaria. This line of experiments has attracted a lot of publicity for its
attempt to identify a synthetic equivalent to a natural compound that is normally
extracted from the sweet wormwood plant that is mostly found in northern China.
Keasling’s lab was able to isolate the metabolic pathway responsible for its manufacture in
the plant and to insert these pathways into yeast to develop the capacity for the
large-scale production of the compound. The task was to re-engineer the most
Deibel Life Sciences, Society and Policy Page 13 of 232014, 10:2
http://www.lsspjournal.com/content/10/1/2efficient artificial pathway (nine genes) that produces artemisinic acid and to convert this,
in a few chemical steps, into an effective antimalaria medicine (see Ro et al. 2006). Also
this type of experimentations relies on the business model of synthetic biology and even
the most humanitarian experiment reflects the exaggeration of the control over the design
of genetic constructs that consists of mostly unknown and unstable biological processes.
As an approach, however, the focus on engineering pathways and the open source model
come together as an approach that seeks to create a design process that requires a much
larger involvement and scope for collaboration. This feature of the open source model will
be discussed below. The main argument is that the involvement of expects, policy-makers
and students is limited by comparison with open source models in informatics. Following
a critical discussion of open source as a response to societal concerns over the risks of
synthetic biology, a comparison will be drawn with the reputation of of open source for
stability an reliability. Considering how the Linux operating system gets much of its
reputation from crashing much less than its proprietary counterparts, is it not the
least to expect from open source in synthetic biology that there is complete openness
about the exaggeration of its capacities?Open source and the users of f synthetic DNA
Bio-safety and bio-security governance are topics that are high on the agenda of policy-
makers. An increasingly popular response is to advocate greater openness as a response.
This includes the open source model of the BioBricks Foundation, which is expected to
mobilize the users of synthetic DNA for the detection of risks alongside students contribute
to experiments.
Firstly, open source has been proposed as a more efficient approach to the risks that
accompany the ability to synthesize the DNA of polio, smallpox, extinct influenza and
dangerous pathogens (see ETC Group 2007b). To address such risks a well-known slogan
of the open source movement is mobilized: the necessity 'to create and maintain open
networks of researchers at every level, thereby magnifying the number of eyes and ears
keeping track of what is going on in the world’ (Carlson 2003: 212). The prevention of
applications that are intended to do harm becomes a responsibility of a scientific
community that collaborates on their design and whose voluntary contributions are
considered as more efficient in the detection of misuse than regulation. The detection of
mistakes depends on making available documentation and creating a transparent
trial-and-error selection in the design process. In brief, openness is expected to remove
the need to trust others not to make mistakes or act with malicious intends when using
the technology (see Johnson 2005, Schmidt 2008).
Secondly, the priority given to the self-management of risks reflects a generally favorable
attitude towards a the ability of users to innovate. Synthetic biology is than one example
among others wherein user-innovation is being underestimated by policy-makers and
manufacturers of various kinds, which applies to working with DNA alongside open source
software and a wide range of physical products (see Von Hippel 2005). The most visible
and popular example in this respect is its student competition, called IGEM, which is held
around the world and lets students do experiments in synthetic biology. Examples include
‘bacteria computing a bit’, e-coli that does not stink but smells like mint, bacteria that move
in patters, that detect light, or that light up and takes pictures (Baker et al. 2006).
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something that even students could do and that the biological parts and components
are already sufficiently manageable to allow students to come up with novel applications.
Accordingly the enrollment of students in experimentation foregrounds the potential to
design synthetic constructs on the basis of voluntary contributions. On the other hand
the inclusiveness of the design community begins to look different when recalling the
business model of synthetic biology and exaggeration of the knowledge about the new
forms of life and related applications that are promised and presented to regulators. The
limitations to collaboration in the life sciences are not only a question of lowering the
threshold to participate in experimentation. The limitations of open source as an
approach to working with synthetic DNA are illustrated in the image below, which shows
an alternative scenario for open source in the life sciences based on language that is loosely
derived from the layout of the website of Ubuntu and has been adapted with Photoshop.
Ubuntu is one of the most used examples of the numerous ‘community developed’ Linux-
based operating systemsm. The picture shows an adaption of one of the pages of its websiteFigure 2 Adapted by the author on the basis of https://wiki.ubuntu.com/Bugs/HowToFix, last
checked may 2013.
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ences. Also its text highlights the importance of users in open source projects in informatics,
which is also prominent in synthetic biology; its purpose, however, is to show the limitations
of an open source approach whose users range from students who are able to contribute to
the design of genetic constructs and synthetic biologists who act as regulators (Figure 2).
Comparing the BioBricks Foundation with openness as implemented in the various
distributions of Linux such as Ubuntu shows that the former has very few possibilities
types of involvement that would lead to different kinds of priorities about what is a stable
release and what is not. Certainly the model in synthetic biology and for open source in the
life sciences involves different kinds of experts to collaborate and set new standards by
sharing information and making their inventions available. It even involves open licensing.
However synthetic biology exaggerates its ability to 'cut' and 'paste' biological modules with
rigidly standardized properties while its notion of ‘the user’ as innovator is minimal when
comparing the design process in synthetic biology with open source in informatics.
Even when involving students in experiments and letting professionals guarantee a
more efficient and self-regulated detection of mistakes in the design of synthetic
constructs, synthetic biology lacks an open process for setting priorities for its designs. This
is explained in the text, which has been adapted to foreground the open source detection
of errors (here called 'bug' as is customary in programming jargon). Following the example
set by the text of Ubuntu highlights that a ‘high priority bug’ does not necessarily involve
high risks like a lethal virus or bio-terrorism. For example there are many bugst that are
important because they have a small impact on a relatively large amount of its users, like
mild anxieties over possible bio-safety issues with synthetic biology that are troublesome to
many of the users of synthetic constructs that run biological functions like ‘energy’,
‘medicine’ and ‘food’.Towards open source as an alternative
There are some signs that there might be a considerable potential for open source
models in the life sciences that are not being realized at this moment, neither in syn-
thetic biology or elsewhere. The potential for a more principled alternative can be
brought into focus by exploring the societal implications of a overtly pragmatic analogy
with open source. Subsequently it becomes possible to suggest a re-orientation, which
is to say that it is to soon too present a fully formed comparison to Linux or that has a
clear relationship to the many societal concerns in play.
Firstly, the main argument of this paper is twofold: (1) there is a convergence with
open source in informatics that ranges from bio-informatics to synthetic biology and
(2) the kind of alternative that is taking shape remains limited. These limitations are
practical as explained above in the discussion of the priority that could be given to the
users of DNA. Furthermore the potential for an alternative can be foregrounded by
briefly comparing the potential for a more principled response that would seek to
re-configure institutions and interests in support of those who possess the skills,
tools and knowledge that are at stake in a world wherein living materials can be
translated into informatic formats and vice versa.
How could an equivalent to a more principled stance on openness be understood?
Such an analogy could begin by revisiting the FSF and its reaction to the
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there is a fully-formed countermovement in place: it is too early days for any attempt
at a comprehensive or definitive overview of the relationship of oepn source to the
many issues on related policy-agendas or the social concerns that might benefit from
such an alternative. Are there, however, any reasons to presume that there could not be
another kind of analogy? What about seeking to mirror the discussion so far: to aim for
an analogy with open source that seeks to follow the example set by the FSF in creating
a bottom-up, transparent and decentralized movement that eventually might show the
kind of innovation that is possible in a design process that does not exclude the priorities
of any of its users?
When open licensing was first introduced, it was not clear whether this was legal and
there were few companies and governments that were interested. Only in early nineties
there began to be widespread recognition of Linux' capacity to innovate. In the decade
that followed the success would result in a movement that had made powerful allies
who had a strong interest in undermining Microsoft’s position in the software market
(see Mackenzie 2005; Deibel 2009). To some extend this situations can already be
observe with open source in synthetic biology, which starts out by being heavily
invested in the formation of markets for sophisticated hardware, software and other
informatic artifacts that are being used in the life sciences. However, the analysis in this
paper has simultaneously shown that there can be open licensing at every point at
which there are intellectual properties, which suggests that there is a basis for projects
that aim to support a notion of open source wherein the user is anyone who wishes to
live and work with DNA on their own terms.
Firstly, the pragmatic alternative that is being proposed can be derived from the
words of BioBricks protagonist Drew Endy who observes that nobody wants:
‘the equivalent of the operating system for wheat in the year 2050 to be running
some, you know, horrendous closed code that crashes all the time and I’ve no idea
what’s going on’ (on the radio program Futures of Biotech 8)n
Obviously he is correct to the extent that nobody would want a crashing operating system
for wheat. There is, however, very little to indicate that the kind of operating system being
designed in synthetic biology is comparable to the safety and stability that Ubuntu and
Linux are known for. The statement signals at the kind of direction that can be expected
from a business model of synthetic biology as a re-materialization of the representation of
DNA in a ‘purely informational form’ – as data or image – [that] will be ‘standing in for
particular materials resources henceforth to be absent’ (Parry 2004: 65).
What this kind of comparison with open source in informatics overlooks is again
how DNA synthesis is a messy and unpredictable process. As the text from the
Ubuntu-website that was shown above has warned, it is necessary to be extremely
careful in the design of a new version of Ubuntu because: 'regression in a stable
release is a catastrophe'. This kind of stability is missing from Endy's wheat, which
seems much more analogous to an operating system that is integrated into the
hardware without revealing its source code. Certainly the designs are released
under an open license, possible the Biobricks license, but Endy's wheat and similar
applications are likely to end up running on organic waste or modified mono-crops that
are patented as usual with the same companies selling even more chemicals and
insecticides than they do now (see Deibel 2013).
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biology might be compared with using a PC's without necessarily knowing its operating
system very well. The profitability of the design of synthetic DNA as a commodity – with
or without patents on DNA – requires the mobilization of specialized knowledge and
commitment of contributers. This kind of involvement is closely tied to the convergence
with informatics, which suggests that the instability caused by commodified mono-crops
does not fall within the scope where priorities for 'debugging' can be decided upon in in
synthetic biology. To put it differently, the really closed source is left in place, which in
this case is about how the usage of crops (like wheat) by farmers and plant breeders has
become increasingly restricted after plant biotechnologies were developed. Genetic
engineering has been a driver of the corporate concentration of multinationals and
leads to integration of the commodity chains for crops, plant biotechnologies and
chemicals (Kloppenburg 2004, Wield et al. 2010, 349).
Furtherore Endy's operating system for wheat and the complications of establishing
who owns a plant and who decides about its usage signals at the relationship between a
certain type of openness with the stagnation of the political agenda for environmental
policy-making.
Specifically the Convention on Biodiversity (CBD), concluded in 1992, was the first to
make explicit that there should be terms and conditions for legitimately searching and
using information that is derived from biodiversity and used in the life sciences. At that
time the text called for the fair and equitable sharing of the benefits arising out of the
utilization of genetic resources (art 1. CBD). This mean that genetic resources came to
be considered as valuable and scarce resource that were at once the basic material of
the life sciences and a potential source of revenue whereby to realize the basic premise
of the CBD: that financial incentives on the destruction of biodiversity should be
replaced by ones that encourage conservation (see Reid et al. 1993, Hayden 2003,
Hamilton 2006, Hoare & Tarasofsky 2007, May & Sell 2006, Lee & Wilkinson
2007, Safrin 2004: 643–647). There appears little potential for negotiations over compen-
sations when there no longer any patents and when the understanding of a reciprocal re-
lationship between science and society is limited to the objective of removing the legal
obstacles to innovation.
This is a scenario that appears when embracing a re-definition of openness as more
efficient without considering whether the momentum and structure of the intellectual
property system need to be used in order to move in a different direction. Initially there
might be very little backing for the need for such an alternative; there will be legal
complications, governments might prefer a notion of openness that is voluntary,
companies would want to see the relationship to a recognizable business model
and public institutions will have to be persuaded. However, there might be different kinds
of companies and significant interest from institutions that seek new legal arrangements
to fit the changing practices in the life sciences. The important point is that open source
principles are already being applied to different ways of working with DNA. Therefore
the selective introduction of the pragmatically oriented models shows the scope for
a more principled approach. The aspiration should be to articulate the possibility
of integrating the various responses into a framework that enables advocacy for a
more principled position that pro-actively seeks to set conditions that prevent
further restrictions on the usage of DNA and aims for an open source model
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to set its priorities.
Despite many hurdles that are much easier to imagine, there are a number of examples
already that begin to show the preliminary contours of an alternative. Among these is the
‘Biological Open Source’ (BIOS) initiative from Australia. What it does is to make available a
package of patented biotechnologies on condition that any follow-up inventions are returned
to the common pool. In other words: anyone who builds upon the contributions of others
must contribute any improvements that are made back to the other participants. No one
that accesses the technologies can enforce intellectual property rights against other members
who signed onto the same termso. However a collaborative approach to genetic techniques
is only a part of the whole; it still excludes users without technical expertise that
might have to live and work with its applications. This limits the appeal of BIOS;
such a project ends up appearing inefficient (in line with the rhetoric of the open
source movement) in the absence of a more principled position as a generalized response
to the commodification of DNA (analogous to the response to the commodification of
source code by the FSF).
What is missing in BIOS, as with the BioBricks GPL and Endy's operating system for
wheat, are the kind of 'bugs' that cannot be solved by genetic engineering and that
require a much more collaborative view of plant breeding. The alternative to 'horrendously
closed code' is than to be able to adapt crops to viruses, particular soil types, specific
climatic conditions and so forth. To follow BIOS' licensing in this direction might begin by
copylefting datasets and genetic circuitries so that their usage is conditional on the support
of farmers’ rights (see Kipp 2005, Aoki 2008, Shrinivas 2006a, 2006b). Furthermore the
open system for genetic techniques could be integrated with a GPL for germplasm for the
breeding of conventional crops within an organizational setting that is truly collaborative
(see Deibel 2009, see Kloppenburg 2010a, b, see Kloppenburg and Deibel 2011). Detailing
such proposals is beyond the scope of this paper but its feasibility should not be dismissed.
Given time and effort a new alliance might be created wherein support for collaborative
projects refers to an approach that allows anyone to file ‘bugs’ on the biological processes,
interactions and reactions in laboratories, fields and bodies.
Obviously there are many question that remain. How to involve the various institutions?
How to meaningfully turn models into a policy agendas? How to incorporate societal
concerns into specific projects? How to prevent the risk of cooperation of this kind of
model by those blind to the dangers of innovation, those that are afraid of technology or
otherwise? Such questions require careful analysis and experimentation, which would
already be a considerable improvement by comparison to the current debate over the merits
of openness, which takes an a-priori position on openness as something beneficial. Opening
up a debate has to begin with the very attempt to seek an alternative to the devaluation of
many of the forms of materiality that are closely linked to societal concerns, particularly
those that involve living and working with DNA in embodied form, like biodiversity, seeds,
medicines and so on.Conclusions
This article ended with a brief observation on 'what open source could be' in the life
sciences. The realization of such an alternative depends on many factors that are
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selectively enabled and constrained in their potential as an alternative in the life sciences.
Throughout the paper it has been affirmed that there is increasing flexibility in regard
of the patenting of DNA and that this should be interpreted as a feature of the convergence
with informatics. This is the main argument of this paper as it sets the stage for any
discussion of the potential of open source as well as the shape of its introduction in the
life sciences. On the one hand, DNA patents do not extend easily to networks of genes
that are understood within biological context that is modeled in its complexity. It is in
experimental settings of this kind that the convergence with informatics is distinguishable
from a juridical orientation on patenting and possible alternatives. On the other hand the
introduction of open source in the life sciences is in the majority of instances an
alternative that is only about the efficiency and capacity of collaboration in programming
and in experimental set- ups. This was explained in the first part of the paper that
focused on the representation of scientific objects as mediated by informatic artifacts,
like supercomputer, numerous kinds of software, databases as well as well as of the most
sophisticated models of cell behavior. The second part highlighted that the patenting of
DNA is not that relevant for the sale and servicing of informatic artifacts, which includes
synthetic biology.
The re-definition of openness in the life sciences can be sharpened by looking at the
kind of open source philosophy that is involved. Accordingly the success of open
source models in the life sciences can vary but this is not solely a question of efficiency;
experimentation that does not depend on patents is prioritized within a context
wherein on companies are attempting to profit from servicing informatic artifacts or
from royalties and performance based payments on the design of whatever biological
commodity is in demand – food stuffs, medicine, hormones, oil and so forth. The
exaggerated emphasis on accuracy and effectiveness in synthetic biology is instructive. As
explained the analogy with open source to the task-oriented biological components in
synthetic biology tends to result in an operating system that runs on the kind of
programming that is much too unstable, that risk crashing because of the interface
with its hardware and its informatic rhetoric.
The example that was used is the student competition for designing BioBricks, which
suggests that synthetic biology could be something that is easy to do. The problem,
however, is that open source programming is not easy, like Linux is not necessarily that
easy to use. It is not the simplest approach that is important, as Linux illustrates; it is
only with releases like Ubuntu that Linux has become available for anyone whereas
earlier it was difficult to obtain, install and operate for those without the necessary
programming skills. Ultimately the potential of open source in the life sciences is
not primarily about the design process for synthetic constructs into something simple or
more profitable but its potential to change the way wherein its designs are being run on
living materials. Not everyone needs to understand and be involved in the most
complicated projects of the life sciences but anyone can be involved in setting
standards for reliability, safety and (food) security.
Such an analogy could become possible by adapting the conditions that open licenses
impose and applying these to the convergence of the life sciences and informatics. The
free availability of information is than a first step towards a form of genetic engineering
of biological parts and systems that is truly optional within an alternative wherein
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that ‘nature is the program; we replicated it; we own it; we are it’ (Haraway 1997: 8).
Obviously this kind of alternative is not the direction chosen in most of the examples;
there is little indication that the simplified notion of well-behaved Bio-Bricks can
be redesigned; that a community of scientists using a GPL would exchange the
optimization of the reactions of genes and proteins for a chance ‘to optimize, enhance and
renormalize what counts as biological’ in society (Thacker 2003: 76). While the conclusion
is therefore that the cases that were discussed are aiming for self-regulation and
prioritizing the removal of any obstacles to the circulation of knowledge and information,
there is still a little bit of time; time to begin making the necessary alliances for another
kind of alternative.
The principled approach of the Free Software Foundation (FSF) might be followed
from a reaction to the commodification of source code in the early eighties to the aim
of removing the restrictions on the usage of DNA in the 2010s and 20s whether as
source code, chemicals, seeds, biodiversity and so on. This is the challenge of open
source in the life sciences: to focus on users not owners, as one of the saying of the
FSF puts it. A response to the commodification of DNA that includes anyone with
a relation to living materials, like those who grow it as crops, eat it as food, take
it as medicine or – by virtue of their bodies – are it.Endnotes
aSee John Conley, The Genomic Law Report. http://www.genomicslawreport.com/
index.php/2013/05/01/some-thoughts-on-myriad-after-the-supreme-court-argument &
See IP Watch, see http://www.ip-watch.org/2013/04/23/us-supreme-court-may-invalidate-
gene-patents-but-create-little-change/ (checked May 2013). See Supreme court opinions.
http://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf
bTypically, software patents are traced back to the 1981 case of Diamond v.
Diehr, as a result of which mathematical algorithms became patentable. Examples
are amazon.com’s one-click and priceline.com’s reverse auction, which are business
patents (for a discussion see Parry 2004).
cSee http://www.gnu.org/philosophy/why-free.html (accessed May 2013) also see
Moglen 2003 and Mako Hill 2005.
dSee for example, http://www.genomesonline.org, and http://www.hupo.org/, www.ncbi.
nlm.nih.gov/Genbank and www.nlm.nih.gov/news/press_releases/dna_rna_100_gig.html
(accessed May 2013).
eOn the Neurocommons see: http://neurocommons.org/page/Main_Page. On the
Hapmap see http://snp.cshl.org/thehapmap.html.en (accessed May 2013).
fsee http://biospice.sourceforge.net/, http://www.open-bio.org/wiki/Main_Page, (accessed
May 2013) .
gThe Blue Brain project includes open source software development called NEURON
(see The Blue Brain Project, http://www.artificialbrains.com/blue-brain-project). The
oldest example of a collaborative and distributed network involved in modeling cells is
probably the Japanese e-cell project from 1996 (Ewan 2004). Another example that
shows the considerable institutional backing of these kinds of networks is the UCSD
'signaling gateway' , which operates by having experts monitor and update two or three
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http://www.lsspjournal.com/content/10/1/2molecules each and peer-review each others work on the thousands of protein
molecules inside the database. These are called Molecule Pages, which are backed
by the journal Nature and include interactive kinds of pre-publication and peer-review;
(Signalling Gateway. http://www.signaling-gateway.org/search/ (accessed May 2013) For
an overview see Allarakhia and Wensley (2007).
hSee http://www.openworm.org/ (accessed May 2013).
iSee http://syntheticbiology.org/ and http://openwetware.org/wiki/The_BioBricks_-
Foundation (accessed May 2013).
jRai and Boyle point to the patent on protein binding that enables basic algebra and
storage capacity – to be useful for molecular computing (Rai & Boyle 2007). Elsewhere
Kumar and Rai give more examples of patents on binding proteins that produce genetic
regulation mechanisms such as multi-state oscillators, a genetic toggle switch, and an
adjustable threshold switch (Kumar & Rai 2007).
kSee the J.Craig Venter Intitute, http://www.jcvi.org/cms/research/projects/synthetic-
bacterial-genome/press-release/ (accessed December 17 2012).
lOn the demise of Codon see Hayden & Ledford 2009 at: http://www.nature.com/
news/2009/090415/full/458818a.html. For more commentary see Rob Carlson, http://
www.synthesis.cc/2009/04/on-the-demise-of-condon-devices.html (accessed May 2013)
mThe model of the image comes from Ubuntu, https://wiki.ubuntu.com/Bugs/
HowToFix (accessed May 2013).
nSee Futures in Biotech 27 – a radio program by Marc Pelletier at: http://www.twit.
tv/fib8 (accessed May 2013).
oBIOS offers a technology package that includes an alternative method for transferring
genes to plants for Monsanto’s Agrobacterium patent (the Agrobacterium-independent
TransBacterTM plant transformation system) and an activity color test that visual-
izes where genes are and what they do (the GUSPLUS). See BIOS, www.bios.net
(accessed May 2013).
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